About Affimed

Breakthrough cancer therapies:
Directing the immune system to eliminate tumor cells
.
 
 
     
 
 
Company Background
 
Affimed was founded in 2000 based on technology developed by the group of Prof. Melvyn Little at the German Cancer Research Center (DKFZ) in Heidelberg. Today, the Company has a pipeline with two clinical-stage product candidates based on this technology. A third clinical-stage product candidate based on Affimed’s platform is being developed by Amphivena, Inc. In 2009, Affimed set up its wholly owned unit AbCheck in Pilsen, Czech Republic, which focuses on fully human antibody screening and optimization. AbCheck offers its cutting-edge services to third party customers and acts as a strategic partner to Affimed by providing integrated research. Affimed is a public company trading on the Nasdaq Global Market under the symbol "AFMD".
 
Affimed’s ROCK® Platform
 
Affimed has used its extensive drug development expertise to generate antibody candidates tailored to different indications, leveraging its proprietary ROCK® platform. ROCK® offers competitive advantages over traditional therapies including highly customizable antibody engagers for tailored treatment options.
 
Read more:  
ROCK® Platform
  Download ROCK® Fact Sheet
 
Corporate Presentation
  Download the most recent Affimed Corporate Presentation
 
 
   

 
 
Company Highlights
 
Affimed’s mission is to develop breakthrough cancer therapies. The company’s approach is to direct the immune system to eliminate tumor cells. Its next generation tetravalent, multi-specific antibodies engage two of the most potent cytotoxic cells of the immune defense arsenal (T cells or natural killer (NK) cells) and link them with high affinity and precision to a tumor cell, thus triggering an attack by the immune cell that ultimately results in the destruction of the tumor cell.

Highlights of the company are:

  Lead product candidate, AFM13, is a first-in-class NK-cell
    mediated cancer immunotherapy.
  Growing pipeline of product candidates focused on key cancer
    indications.
  Retained global commercial rights for three candidates in the
    product pipeline.
  Experienced management team with a strong track record in
    the development and commercialization of new medicines.
  Strong technology base and solid patent portfolio in the field
    of targeted immuno-oncology.
 
 
 
 
Clinical Development Candidates
 
 
Manager
 
     



  Impressum Disclaimer Data Privacy